Skip to main content

Catalyst Calendar

Scope

Thu, Aug 13, 2026

1 updates
MGNX
4:05 PM

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)

Presentation / Abstract • Phase 1ESMO 2026 Congress poster presentation Thu, Oct 1, 2026macrogenics.com

Tue, Aug 11, 2026

1 updates

Thu, Jul 23, 2026

1 updates
MGNX
4:01 PM

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design Ongoing enrollment in other tumor-specific cohorts,

Presentation / Abstract • Phase 1ESMO poster presentation Fri, Oct 23, 2026, 3:15 PM CESTmacrogenics.com

Thu, Jul 2, 2026

1 updates

Mon, Jun 22, 2026

1 updates